PuSH - Publikationsserver des Helmholtz Zentrums München

Müller, D.* ; Danner, M.* ; Schmutzler, R.* ; Engel, C.* ; Wassermann, K.* ; Stollenwerk, B. ; Stock, S.* ; Rhiem, K.*

Economic modeling of risk-adapted screen-and-treat strategies in women at high risk for breast or ovarian cancer.

Eur. J. Health Econ. 20, 739-750 (2019)
Postprint DOI Verlagsversion bestellen
Open Access Green
BACKGROUND: The 'German Consortium for Hereditary Breast and Ovarian Cancer' (GC-HBOC) offers women with a family history of breast and ovarian cancer genetic counseling. The aim of this modeling study was to evaluate the cost-effectiveness of genetic testing for BRCA 1/2 in women with a high familial risk followed by different preventive interventions (intensified surveillance, risk-reducing bilateral mastectomy, risk-reducing bilateral salpingo-oophorectomy, or both mastectomy and salpingo-oophorectomy) compared to no genetic test. METHODS: A Markov model with a lifelong time horizon was developed for a cohort of 35-year-old women with a BRCA 1/2 mutation probability of ≥ 10%. The perspective of the German statutory health insurance (SHI) was adopted. The model included the health states 'well' (women with increased risk), 'breast cancer without metastases', 'breast cancer with metastases', 'ovarian cancer', 'death', and two post (non-metastatic) breast or ovarian cancer states. Outcomes were costs, quality of life years gained (QALYs) and life years gained (LYG). Important data used for the model were obtained from 4380 women enrolled in the GC-HBOC. RESULTS: Compared with the no test strategy, genetic testing with subsequent surgical and non-surgical treatment options provided to women with deleterious BRCA 1 or 2 mutations resulted in additional costs of €7256 and additional QALYs of 0,43 (incremental cost-effectiveness ratio of €17,027 per QALY; cost per LYG: €22,318). The results were robust in deterministic and probabilistic sensitivity analyses. CONCLUSION: The provision of genetic testing to high-risk women with a BRCA1 and two mutation probability of ≥ 10% based on the individual family cancer history appears to be a cost-effective option for the SHI.
Weitere Metriken?
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Brca ; Breast Cancer ; Cost-effectiveness ; Economic Modeling ; Genetic Testing ; Risk-reducing Surgery
ISSN (print) / ISBN 1618-7598
e-ISSN 1439-6637
Zeitschrift The European journal of health economics
Quellenangaben Band: 20, Heft: 5, Seiten: 739-750 Artikelnummer: , Supplement: ,
Verlag Springer
Verlagsort Berlin ; Heidelberg